ABSTRACT

For the upfront adjuvant therapy of postmenopausal estrogen receptor–positive breast cancer, the third-generation aromatase inhibitors (AIs) have shown a more favourable overall risk–benefit profile than has tamoxifen. Benefits of the AIs include less frequent gynecologic, cerebrovascular, and thromboembolic adverse events; greater disease-free survival; and lower tumour recurrence. Although approximately 25% of postmenopausal women with early breast cancer report experiencing symptoms of arthralgia with AI therapy, 68-month data from the Arimidex, Tamoxifen, Alone or in Combination trial showed that, compared with tamoxifen, anastrozole treatment was associated with only a modest increase in the incidence of joint symptoms. The events, which were mostly mild-to-moderate in intensity, led to treatment withdrawal in 2% of patients on anastrozole as compared with 1% in the tamoxifen arm. The symptoms and changes correlate with clinical, biochemical, and radiologic findings in symptomatic women. To determine appropriate intervention, it is therefore essential to perform a comprehensive evaluation of musculoskeletal complaints to distinguish natural menopause-related degenerative disease from AI-related effects. The present review explores the advantages of differential diagnosis with an emphasis on history and physical and musculoskeletal examination; laboratory investigations are used to corroborate or rule out clinical impressions. The transient symptoms associated with the AIs are manageable with an appropriate combination of lifestyle changes, including exercise and joint protection in conjunction with pharmacologic approaches.

KEY WORDS

Arthralgia, arthritis, aromatase inhibitors, breast cancer

1. INTRODUCTION

The benefit of aromatase inhibitors (AIs) in the treatment of hormone-dependent early breast cancer is now well established, leading to a recommendation for their use as adjuvant therapy in postmenopausal women. The underlying rationale for adjuvant treatment of early-stage breast cancer following primary therapy is to prevent or delay recurrence, although the goal is also to increase the time to progression of the tumour and to improve overall survival. Although disease-free survival is approximately 5 times longer in cases of early-stage disease than in cases of metastatic breast cancer, patients at early stages of breast cancer who receive adjuvant endocrine therapy still need to understand the safety and toxicity of the treatment.

2. MUSCULOSKELETAL COMPLAINTS WITH AIs

Although the AIs are associated with fewer thromboembolic events and endometrial abnormalities than is tamoxifen, approximately 25% of postmenopausal women on AIs report arthralgia, skeletal, and muscle pain.

The multicentre double-blind placebo-controlled MA.17 trial by the National Cancer Institute of Canada Clinical Trials Group compared 5 years of letrozole therapy with 5 years of placebo in 5187 postmenopausal women with breast cancer. The trial revealed marked increases in arthralgia (25% vs. 21%) and myalgia (15% vs. 12%) in patients on letrozole as compared with those on placebo.

The Intergroup Exemestane Study, which enrolled 4742 postmenopausal women with hormone receptor–positive or unknown breast cancer, has also shown a link between arthralgia and the AI exemestane (5.4% exemestane vs. 3.6% tamoxifen). The Arimidex, Tamoxifen Alone or in Combination (ATAC) trial, which involved 9366 postmenopausal women with localized breast cancer following surgery, was one of the largest trials to investigate a third-generation AI as adjuvant therapy for breast cancer. In ATAC, after 68 months’ median follow-up, the incidence of arthralgia was significantly higher in the anastrozole group than in the tamoxifen group [1100 of 3092 (35.6%) vs. 911 of 3094 (29.4%) patients]. In fact, as compared with tamoxifen, anastrozole treatment was associated with only a modest increase in the
incidence of arthralgia. Nearly half (46%) of patients with arthralgia syndrome reported exacerbation of a pre-existing joint condition. Symptoms appeared within the first 2 years of AI therapy (anastrozole 68%, tamoxifen 59%), with a peak incidence at 6 months (anastrozole 29%, tamoxifen 20%). However, half of the patients who recovered were symptom-free within 6 months of onset, and in 75% of patients, symptoms resolved within 18 months. Most events were mild to moderate in intensity, and only a small fraction of patients (2% with anastrozole and 1% with tamoxifen) discontinued treatment because of bone symptoms.

2.1 Menopausal Arthritis and AI-Induced Arthralgia

The prevalence of joint pain in the knees, hands, feet, and other joints increases with age in women, reaching a maximum in the group 50 to 59 years of age, implicating hormonal changes. The prevalence of osteoarthritis increases around menopause, and rheumatoid arthritis has its highest incidence and prevalence in the decade following menopause, perhaps triggered by estrogen deprivation.

The physiologic underpinnings of joint pain involve activation, by inflammatory mediators such as prostaglandins and bradykinin, of the nociceptive fibres innervating the articular structures. Activated nociceptors increase sensitivity to pain caused by a stimulus, including a mechanical stimulus. Inflammation leading to expansion of the nocicepter’s receptor field enhances neural transmission and the overall pain perception. The neuroprotective, anti-inflammatory and anti-nociceptive activities of estrogen are believed to be mediated by estrogen receptors present in the spinal cord and brain. Low estrogen levels (resulting from aromatization of androgens) may therefore have a protective effect by directly affecting opioid pain fibres in the central nervous system and preventing inhibition of nociceptive neurons. Estrogen depletion during AI therapy of postmenopausal early and advanced breast cancer results in enhanced nociception and higher rates of arthralgia than are seen with tamoxifen.

Unfortunately, coexisting conditions such as degenerative joint disease, fibromyalgia, osteoporosis, and degenerative disc disease contribute to worsening of the arthralgia or bone pain syndrome. Arthralgia is a known side-effect of some medications, including angiotensin converting-enzyme inhibitors, proton pump inhibitors, quinolones, and tibolones. Postmenopausal status is also an independent predictor of increased musculoskeletal pain, with estrogen deprivation contributing to arthralgia during menopause and aromatase inhibition exacerbating painful symptoms by further estrogen reduction.

The complex challenge facing the physician is therefore to accurately distinguish arthralgia associated with AI therapy from bone disease and inflammatory and degenerative arthropathies, and from pain secondary to other diseases. Tables 1 and 2 summarize the various features of articular and nonarticular, and inflammatory and non-inflammatory joint pain respectively.

2.2 Clinical Evaluation of Musculoskeletal Complaints

In the preliminary assessment of musculoskeletal complaints, the emphasis is on patient history and physical examination. Patients may describe stiffness, aching, or pain in the hands, arms, knees, feet, pelvic and hip bones, or back, which may be temporarily associated with the start of AI therapy. This discomfort is usually symmetrical, and may be associated with mild soft-tissue thickening. The physician should rule out conditions that require immediate attention, including a history of significant trauma, a hot and swollen joint, acute severe pain, fever, weight loss, malaise, focal or diffuse muscle weakness, burning, numbness, paresthesia, and claudication (Figure 1).

The next step entails determining whether the condition is articular (pauci-articular, involving 3 or fewer joints, or poly-articular, involving more than 3 joints) or non-articular; inflammatory or non-inflammatory; and acute (less than 6 weeks’ duration) or chronic (6 weeks’ duration or longer). Complaints of “joint pain” may originate from the joint itself or from periarthicular loci such as adjacent bone, ligaments, tendons, bursae, or soft tissues (Figure 1).

2.2.1 Medical History

Appropriate medical history should include investigation of the co-morbidities linked with musculoskeletal complaints: inflammatory bowel disease (IBD), psoriasis, reactive arthritis, hemochromatosis, and hypothyroidism. All medications should be reviewed as completely as possible, including diuretics, antihypertensives, anticonvulsants, cholesterol-lowering agents, and others. Social history should be examined for work, sexuality, living, travel, and familial patterns of connective tissue disease, psoriasis, and gout. A systems review should also be undertaken to note any other symptoms or infections of the gastrointestinal, genitourinary, ocular, and skin systems.

2.2.2 Physical and Musculoskeletal Examination

During the physical examination, the physician should check for the presence of extra-articular features, including nodules, tophi, or skin rashes (psoriasis), or the presence of renal, pulmonary, neurologic, or ocular signs or symptoms. Any joint effusion may originate from the joint itself or from periarthicular loci such as adjacent bone, ligaments, tendons, bursae, or soft tissues. Lyme arthritis should be considered in patients with
new persistent inflammatory features—including effusions—in regions where Lyme disease is endemic, or in patients with a history of travel to an endemic area. Synovitis is usually indicated by the presence of “stress pain” or an effusion.

Mal-alignment and bony enlargement may suggest advanced osteoarthritis. On the other hand, joint tenderness with full and painless passive range of motion may indicate a peri-arthritis, including bursitis, tendonitis, tenosynovitis, or enthesitis, but no inflammation of the synovial lining of the joint space (Figure 1, Table 1) 25.

### 2.2.3 Inflammation

The pattern and number of inflamed joints should be observed: acute monoarthritis may represent septic arthritis or crystal arthritis (gout, for instance; Table II). Oligoarthritis or polyarthritis involving the hands and wrists but not the distal interphalangeal joints is suggestive of rheumatoid arthritis. Early symptoms of rheumatoid arthritis include morning stiffness (more than 30 minutes) and three or more swollen joints accompanied by metacarpophalangeal or metatarsophalangeal involvement, which may be simply demonstrated with the “squeeze test” 29.
FIGURE 1 Algorithm for assessment of musculoskeletal complaints (adapted).
Psoriasis and osteoarthritis should be suspected if the distal interphalangeal and proximal interphalangeal joints are involved. Gonococcal arthritis, Rubella, and acute rheumatic fever may present with a migratory polyarthritis. Spondyloarthropathy such as ankylosing spondylitis, reactive arthritis (formerly Reiter syndrome), psoriatic arthritis, or arthropathy of IBD involve peripheral joints, enthuses, and whole digits (dactylitis).

Myalgias and stiffness of the shoulder and pelvic girdle that occur in patients more than 50 years of age may be suggestive of polymyalgia rheumatica.
Infection, metastatic malignancy, or neurologic causes must be ruled out when evaluating new low back pain in this group of patients.

2.2.4 Laboratory Investigation
The laboratory test that is most useful for evaluating patients with inflammatory arthritis and an effusion is synovial fluid analysis (Table II). The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) test are non-specific and may be elevated with other conditions, including malignancy and infection. Rheumatoid factor is also non-specific and increases with age, regardless of the presence or absence of joint disease. Patients with connective tissue diseases, diffuse musculoskeletal symptoms, or drug-induced diseases may have positive antinuclear antibodies.

2.3 Investigation of AI-Associated Arthralgia
The pathogenic and anatomic features of AI-induced arthralgia have not been clearly delineated, but the musculoskeletal symptoms and changes have been investigated at the clinical, biochemical, and radiologic levels in symptomatic women. For instance, after an average of 8 weeks’ treatment, the symptoms most commonly reported with anis such as letrozole or exemestane have been severe early morning stiffness and hand–wrist pain. Clinical signs included severely limited mobility in the affected part of the hand or wrist. “Trigger finger” and carpal tunnel syndrome were the most frequently reported clinical signs, but inflammatory disease was ruled out in the absence of elevation in CRP or ESR, although those tests have not been assessed for sensitivity or specificity in this population. However, ultrasound examination showed fluid in the tendon sheath surrounding the digital flexor tendons. Magnetic resonance imaging (MRI) in various patients showed fluid in the tendon sheaths of the digital flexor muscles, intra-articular fluid accumulation in the metacarpal joints, and synovitis of the radiocarpal joint. Because of the prevalence of abnormal or unexpected findings in asymptomatic patients, MRI of the spine and computed tomography should be reserved for patients targeted for surgical intervention or those in whom tumor or infection is a concern. Laboratory and radiographic studies should be used to corroborate clinical impressions or to rule out causes that should not be missed. Systematic clinical re-evaluation is imperative in the event of uncertain diagnosis.

2.4 Management of Arthralgia
Studies reveal that the three most common sites of arthralgia, in descending order, are knees, hands and wrists, and shoulders, with the median severity scores of AI-related joint symptoms being 7 for pain and 6 for stiffness on a scale of 0–10. However, more than half of patients with AI-associated joint symptoms reported relief with medications or supplements. Of those taking an analgesic, 41% took acetaminophen, 59% took a nonsteroidal anti-inflammatory drug (NSAID), and 12% took other medications. The median score for relief achieved with oral medications was 7. In addition, 55% of patients used non-pharmacologic interventions, mainly exercise, to alleviate joint symptoms.

Compared with patients receiving tamoxifen, patients receiving anastrozole had only a modest increase in joint symptoms, and most reported symptoms that were mild to moderate in intensity, eliminating the need for treatment withdrawal. Indeed, more than 90% of patients treated for anastrozole-induced joint aches and pains were managed with an NSAID alone or in combination with mild analgesics.

The most appropriate intervention for pain management in AI-associated arthralgia may be a combination of lifestyle changes, such as introducing weight-bearing exercise, abstaining from smoking, being moderate in alcohol consumption, and taking dietary calcium supplements and vitamin D for bone protection in conjunction with pharmacologic approaches. Figure 2 contains a proposed algorithm for the management of musculoskeletal symptoms in patients taking an AI.

2.4.1 Non-pharmacologic Approaches to the Management of Arthralgia
Chronic pain may be relieved either with heat, in the form of warm showers or hot massage, or with acupuncture and acupressure techniques or transcutaneous electrical nerve stimulation. However, patients with spinal osteoporosis should avoid deep muscle massage. Preliminary results in more than a dozen eligible patients investigated at the Columbia University College of Physicians and Surgeons suggested that acupuncture could be a potentially useful intervention for improvements in index measures of body pain and osteoarthritis.

Pain associated with arthralgia of the knees may also be managed through patellar taping and appropriate footwear with lateral wedged insoles. Pain associated with arthralgia in postmenopausal breast cancer patients on adjuvant endocrine therapy: a risk–benefit analysis. Poster presentation at the Lynn Sage Breast Cancer Symposium; Chicago, IL; October 6–9, 2005). Furthermore, regular stretching, joint mobility exercises and physiotherapy to regain strength, increase flexibility, relieve tension, and reduce fatigue are recommended. In addition, psychotherapy including relaxation training, biofeedback, visual imagery, distraction methods, and psychiatric intervention could effectively alleviate pain-related emotional stress and depression, given the increased mood, anxiety, and substance use disorders seen in patients with musculoskeletal disorders, according to a large Canadian community health survey.
FIGURE 2  Management of musculoskeletal symptoms in patients with early breast cancer taking an aromatase inhibitor. † Misoprostol or proton pump inhibitor. COX-2 = cyclooxygenase 2; IA = intra-articular; NSAID = nonsteroidal anti-inflammatory drug; OTC = over-the-counter; TCA = tricyclic antidepressant.

### 2.4.2 Pharmacologic Approaches

Table III presents some pharmacologic options for pain relief. Drug therapy for amelioration of pain symptoms includes acetaminophen, NSAIDs such as naproxen, mild opiates, strong opiates, and glucosamine. Combination analgesics (for example, acetaminophen with codeine or oxycodone) may be used to provide additional short-term relief. Inhibitors of COX-2 may be a good choice when NSAIDs are contraindicated. As well, topical medications such as capsaicin and methylsalicylate may provide pain relief. Antidepressants may help in the event of comorbid depression associated with chronic pain.

Bisphosphonates have been associated with modest adjunctive analgesic benefits, but little clinical evidence is available to support their use in early-stage breast cancer. By helping to rebuild the microarchitecture of bone, bisphosphonates may offer women with early breast cancer some relief from arthralgia. The correlation of AI-associated arthralgia with a low body mass index is still not clearly established, although several possible mechanisms associate the phenomenon with an incidence of microfractures and local activation of inflammatory mediators.

| Medication          | Dosage                        |
|---------------------|-------------------------------|
| Acetaminophen       | ≤4 g daily (consider ER)      |
| NSAID               | Naproxen: 500–750 mg daily (analgesia) 1000–1500 mg daily (inflammation) |
| Cyclooxygenase inhibitors | Celecoxib: 100–200 mg daily b |
| Tramadol            | ≤400 mg daily (consider ER)   |
| Narcotics           | Codeine versus oxycodone      |
| Pain modifiers      | TCA: nortriptyline 10–100 mg daily Gabapentin, pregabalin |
| Intra-articular steroids | Methylprednisolone acetate, triamcinolone suspension: 40 mg/cm³ |
3. CONCLUSION

Adverse events such as arthralgia and myalgia are more frequent with adjuvant AI therapy than with tamoxifen. However, they are predictable and may be easily managed with appropriate lifestyle changes and non-pharmacologic interventions, or with pain medications after accurate musculoskeletal evaluation and differential diagnosis. Although a few studies suggest the use of bisphosphonates to manage bone-related side effects, current evidence is insufficient to support the use of these agents in preventing skeletal events or improving survival in women with early-stage breast cancer. Although the association of estrogen deprivation with osteoarthritis and rheumatoid arthritis in postmenopausal women needs further study, it is essential to understand that the symptoms are usually transient and resolve when the AIs are discontinued at the end of therapy.

4. REFERENCES

1. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619–29.
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2005;16:1569–83.
3. National Institute for Health and Clinical Excellence (NICE). Hormonal Therapies for the Adjuvant Treatment of Early Oestrogen Receptor Positive Breast Cancer. London, U.K.: NICE; 2006.
4. Blamey RW. Guidelines on endocrine therapy of breast cancer. Eur J Cancer 2002;38:615–34.
5. Gradishar WJ. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005;69:1–9.
6. Morales L, Pans S, Westhovens R, et al. Importance of synovial fluid retention and thickening in patients with severe musculoskeletal pains treated with letrozole or exemestane: a case series describing the impact of symptoms, clinical findings and magnetic resonance imaging [abstract 4056]. Breast Cancer Res Treat 2006;100(suppl 1).
7. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–71.
8. Coombs RC, Hall E, Gibson LJ, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.
9. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–2.
10. Buzdar AU, on behalf of the ATAC trialists’ group. Clinical features of joint symptoms observed in the Arimidex, Tamoxifen Alone or Combination (ATAC) trial [abstract 551]. Proc Am Soc Clin Oncol 2006;24:18s.
11. Wolfe F, Ross K, Anderson J, Russell JI, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19–28.
12. Croft P, Rigby AS, Boswell R, Schollum J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993;20:710–13.
13. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41:1343–55.
14. Doran MF, Pond GR, Crowson CS, O’Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625–31.
15. Kidd BL, Photiou A, Inglis JJ. The role of inflammatory mediators on nociception and pain in arthritis. Novartis Found Symp 2004;260:122–33.
16. D’Agostino P, Milano S, Barbera C, et al. Sex hormones modulate inflammatory mediators produced by macrophages. Ann N Y Acad Sci 1999;876:426–9.
17. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis: the second decade. Endocrinology 1998;139:2659–61.
18. Flores CA, Shughue P, Petersen SL, Mokha SS. Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 2003;118:769–78.
19. Blomqvist A. Sex hormones and pain: a new role for brain aromatase? J Comp Neurol 2000;423:549–51.
20. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–802.
21. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357–66.
22. Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 1999;17:52–63.
23. Presant CA, Kelly C, Bosserman L, et al. Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): frequency and characterization in clinical practice [abstract]. J Clin Oncol 2006;24(suppl): 6137.
24. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005;52:2594–8.
25. Phillips A, Polisson RP. The rational initial clinical evaluation of the patient with musculoskeletal complaints. Am J Med 1997;103:75–81s.
26. American College of Rheumatology, Ad Hoc Committee on Clinical Guidelines. Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. Arthritis Rheum 1996;39:1–8.
27. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. *J Clin Oncol* 2007;25:3797–9.

28. Holbrook AM (Chair) for the Ontario Musculoskeletal Therapy Review Panel. *Ontario Treatment Guidelines for Osteoarthritis, Rheumatoid Arthritis, and Acute Musculoskeletal Injury*. Toronto: Queen’s Printer; 2000.

29. Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. *J Rheumatol Suppl* 2002;66:3–8.

30. Jensen MC, Brant–Zawadzki MN, Obuchowski N, Modic MT, Malkasian D, Ross JS. Magnetic resonance imaging of the lumbar spine in people without back pain. *N Engl J Med* 1994; 331:69–73.

31. Crew KD, Apollo A, Greenlee H, et al. Prevalence of joint symptoms in postmenopausal women on aromatase inhibitors for early stage breast cancer [abstract 5068]. *Breast Cancer Res Treat* 2006;100(suppl 1).

32. American College of Rheumatology, Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. *Arthritis Rheum* 2000;43:1905–15.

33. National Institutes of Health, Osteoporosis and Related Bone Diseases, National Resource Center. Osteoporosis: coping with chronic pain [Web page]. Bethesda: National Institutes of Health; March 2005. [Available at: www.niams.nih.gov/bone/hi/osteoarthritis_pain.htm; cited July 2007]

34. Crew KD, Capodice J, Greenlee H, et al. Effect of acupuncture on joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients [abstract 5071]. *Breast Cancer Res Treat* 2006;100(suppl 1).

35. Patten SB, Williams JV, Wang J. Mental disorders in a population sample with musculoskeletal disorders. *BMC Musculoskeletal Disord* 2006;7:37.

36. Evans D, Charney D, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. *Biol Psychiatry* 2005;58:175–89.

37. Warr D, Johnston M, and the members of the Breast Cancer Disease Site Group. *Use of Bisphosphonates in Women with Breast Cancer*. Practice Guideline Report #1-11. Toronto: Cancer Care Ontario, Program in Evidence-based Care; April 2004.

38. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. *Cochrane Database Syst Rev* 2005;3:CD003474.

39. Boonen S, Haentjens P, Vandeven L, Vanderschueren D. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. *J Intern Med* 2004; 255:1–12.

40. Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. *Breast J* 2007;13:28–35.

**Correspondence to:** Carter Thorne, The Arthritis Program, Southlake Regional Health Centre, 43 Lundy’s Lane, Newmarket, Ontario L3Y 3R7.

**E-mail:** cartho@rogers.com